Evidence map›Paper›PMID 30417868›Full record

ArticleJournal of visualized experiments : JoVE2018

Automation of a Positron-emission Tomography (PET) Radiotracer Synthesis Protocol for Clinical Production.

Eric Schopf, Christopher M Waldmann, Jeffrey Collins, Christopher Drake, Roger Slavik, R Michael van Dam

Abstract readVideo-Audio Media
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of visualized experiments : JoVE, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Development and Optimization ofACS pharmacology & translational science · 2023
    Review
  2. Translating a radiolabeled imaging agent to the clinic.Advanced drug delivery reviews · 2022
    Review
  3. Method to Development of PET Radiopharmaceutical for Cancer Imaging.Methods in molecular biology (Clifton, N.J.) · 2022
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Eric SchopfSOFIE.
Christopher M WaldmannDepartment of Molecular & Medical Pharmacology, David Geffen School of Medicine, University of California, Los Angeles (UCLA); Ahmanson Translational Imaging Division, University of California, Los Angeles (UCLA).
Jeffrey CollinsDepartment of Molecular & Medical Pharmacology, David Geffen School of Medicine, University of California, Los Angeles (UCLA); Crump Institute for Molecular Imaging, University of California, Los Angeles (UCLA).
Christopher DrakeSOFIE.
Roger SlavikDepartment of Molecular & Medical Pharmacology, David Geffen School of Medicine, University of California, Los Angeles (UCLA); Ahmanson Translational Imaging Division, University of California, Los Angeles (UCLA); RSlavik@mednet.ucla.edu.
R Michael van DamDepartment of Molecular & Medical Pharmacology, David Geffen School of Medicine, University of California, Los Angeles (UCLA); Crump Institute for Molecular Imaging, University of California, Los Angeles (UCLA); mvandam@mednet.ucla.edu.

Funding

A Novel PET Probe for Use in Cancer DiagnosticsR44CA216539 · NCI · SOFIE BIOSCIENCES, INC. · PI MOORE, MELISSA · 2017 to 2018
$2.0M
NCI NIH HHS R44 CA216539
6 · The paper itself

Abstract

The development of new positron-emission tomography (PET) tracers is enabling researchers and clinicians to image an increasingly wide array of biological targets and processes. However, the increasing number of different tracers creates challenges for their production at radiopharmacies. While historically it has been practical to dedicate a custom-configured radiosynthesizer and hot cell for the repeated production of each individual tracer, it is becoming necessary to change this workflow. Recent commercial radiosynthesizers based on disposable cassettes/kits for each tracer simplify the production of multiple tracers with one set of equipment by eliminating the need for custom tracer-specific modifications. Furthermore, some of these radiosynthesizers enable the operator to develop and optimize their own synthesis protocols in addition to purchasing commercially-available kits. In this protocol, we describe the general procedure for how the manual synthesis of a new PET tracer can be automated on one of these radiosynthesizers and validated for the production of clinical-grade tracers. As an example, we use the ELIXYS radiosynthesizer, a flexible cassette-based radiochemistry tool that can support both PET tracer development efforts, as well as routine clinical probe manufacturing on the same system, to produce [

Indexed as

AutomationHumansPositron-Emission TomographyRadiochemistryRadiopharmaceuticalsSoftwareRadiopharmaceuticals

Identifiers

PMID30417868
PMCPMC6235612

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.